Skip to main content
Erschienen in: Diabetologia 2/2006

01.02.2006 | Article

Elevated plasma phospholipid transfer protein activity is a determinant of carotid intima-media thickness in type 2 diabetes mellitus

verfasst von: R. de Vries, G. M. Dallinga-Thie, A. J. Smit, B. H. R. Wolffenbuttel, A. van Tol, R. P. F. Dullaart

Erschienen in: Diabetologia | Ausgabe 2/2006

Einloggen, um Zugang zu erhalten

Abstract

Aim/hypothesis

The plasma activity of phospholipid transfer protein (PLTP), which has putative pro- and anti-atherogenic roles in lipoprotein metabolism, is increased in type 2 diabetes mellitus. We analysed the relationship between carotid artery intima–media thickness (IMT), an established marker of atherosclerosis, and PLTP activity in diabetic patients and control subjects.

Methods

The IMT (mean of three segments in both carotid arteries by ultrasonography), clinical variables, plasma PLTP activity (phospholipid vesicle–HDL system), lipoproteins, C-reactive protein and insulin were measured in 87 non-smoking men and women, who had type 2 diabetes mellitus, no cardiovascular disease, and were not on insulin or lipid-lowering medication, and in 83 age-matched control subjects.

Results

In diabetic patients, carotid IMT (p=0.02), pulse pressure (p=0.003), plasma PLTP activity (p<0.001), triglycerides (p=0.01), C-reactive protein (p<0.01) and insulin (p<0.001) were higher, whereas HDL cholesterol was lower (p<0.001) than in control subjects. Multiple stepwise linear regression analysis demonstrated that in type 2 diabetic patients IMT was independently associated with age (p<0.001), sex (p=0.001), pulse pressure (p=0.003), plasma PLTP activity (p=0.03) and HDL cholesterol (p=0.03), but not with very low density lipoprotein+LDL cholesterol, triglycerides, C-reactive protein and insulin (all p>0.20). The relationship between plasma PLTP activity and IMT was not significant in control subjects.

Conclusions/interpretation

Plasma PLTP activity is a positive determinant of IMT in type 2 diabetes mellitus, suggesting that high PLTP activity is involved in accelerated atherosclerosis in this disease.
Literatur
1.
Zurück zum Zitat Tall AR, Krumholz S, Olivecrona T, Deckelbaum RJ (1985) Plasma phospholipid transfer protein enhances transfer and exchange of phospholipids between very low density lipoproteins and high density proteins during lipolysis. J Lipid Res 26:842–851PubMed Tall AR, Krumholz S, Olivecrona T, Deckelbaum RJ (1985) Plasma phospholipid transfer protein enhances transfer and exchange of phospholipids between very low density lipoproteins and high density proteins during lipolysis. J Lipid Res 26:842–851PubMed
3.
Zurück zum Zitat Jauhiainen M, Metso J, Pahlman R, Blomqvist S, Van Tol A, Ehnholm C (1993) Human plasma phospholipid transfer protein causes high density lipoprotein conversion. J Biol Chem 268:4032–4036PubMed Jauhiainen M, Metso J, Pahlman R, Blomqvist S, Van Tol A, Ehnholm C (1993) Human plasma phospholipid transfer protein causes high density lipoprotein conversion. J Biol Chem 268:4032–4036PubMed
4.
Zurück zum Zitat Von Eckardstein A, Jauhiainen M, Huang Y et al (1996) Phospholipid transfer protein mediated conversion of high density lipoproteins generates pre b1-HDL. Biochim Biophys Acta 1301:255–262 Von Eckardstein A, Jauhiainen M, Huang Y et al (1996) Phospholipid transfer protein mediated conversion of high density lipoproteins generates pre b1-HDL. Biochim Biophys Acta 1301:255–262
5.
Zurück zum Zitat Settasatian N, Duong M, Curtiss LK et al (2001) The mechanism of the remodeling of high density lipoproteins by phospholipid transfer protein. J Biol Chem 276:26898–26905PubMedCrossRef Settasatian N, Duong M, Curtiss LK et al (2001) The mechanism of the remodeling of high density lipoproteins by phospholipid transfer protein. J Biol Chem 276:26898–26905PubMedCrossRef
6.
Zurück zum Zitat Jiang X, Francone OL, Bruce C et al (1996) Increased prebeta-high density lipoprotein, apolipoprotein AI, and phospholipid in mice expressing the human phospholipid transfer protein and human apolipoprotein AI transgenes. J Clin Invest 98:2373–2380PubMedCrossRef Jiang X, Francone OL, Bruce C et al (1996) Increased prebeta-high density lipoprotein, apolipoprotein AI, and phospholipid in mice expressing the human phospholipid transfer protein and human apolipoprotein AI transgenes. J Clin Invest 98:2373–2380PubMedCrossRef
7.
Zurück zum Zitat Van Haperen R, Van Tol A, Vermeulen P et al (2000) Human plasma phospholipid transfer protein increases the antiatherogenic potential of high density lipoproteins in transgenic mice. Arterioscler Thromb Vasc Biol 20:1082–1088PubMed Van Haperen R, Van Tol A, Vermeulen P et al (2000) Human plasma phospholipid transfer protein increases the antiatherogenic potential of high density lipoproteins in transgenic mice. Arterioscler Thromb Vasc Biol 20:1082–1088PubMed
8.
Zurück zum Zitat Lie J, De Crom R, Van Gent T et al (2002) Elevation of plasma phospholipid transfer protein in transgenic mice increases very low density lipoprotein secretion. J Lipid Res 43:1875–1880PubMedCrossRef Lie J, De Crom R, Van Gent T et al (2002) Elevation of plasma phospholipid transfer protein in transgenic mice increases very low density lipoprotein secretion. J Lipid Res 43:1875–1880PubMedCrossRef
9.
Zurück zum Zitat Van Haperen R, Van Tol A, Van Gent T et al (2002) Increased risk of atherosclerosis by elevated plasma levels of phospholipid transfer protein. J Biol Chem 277:48938–48943PubMedCrossRef Van Haperen R, Van Tol A, Van Gent T et al (2002) Increased risk of atherosclerosis by elevated plasma levels of phospholipid transfer protein. J Biol Chem 277:48938–48943PubMedCrossRef
10.
Zurück zum Zitat Jiang XC, Qin S, Qiao C et al (2001) Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency. Nat Med 7:847–852PubMedCrossRef Jiang XC, Qin S, Qiao C et al (2001) Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency. Nat Med 7:847–852PubMedCrossRef
11.
Zurück zum Zitat Jiang X, Tall AR, Qin S et al (2002) Phospholipid transfer protein deficiency protects circulating lipoproteins from oxidation due to the enhanced accumulation of vitamin E. J Biol Chem 277:31850–31856PubMedCrossRef Jiang X, Tall AR, Qin S et al (2002) Phospholipid transfer protein deficiency protects circulating lipoproteins from oxidation due to the enhanced accumulation of vitamin E. J Biol Chem 277:31850–31856PubMedCrossRef
12.
Zurück zum Zitat Yang X, Yan D, Qiao C et al (2003) Increased atherosclerotic lesions in apoE mice with plasma phospholipid transfer protein overexpression. Arterioscler Thromb Vasc Biol 23:1601–1607PubMedCrossRef Yang X, Yan D, Qiao C et al (2003) Increased atherosclerotic lesions in apoE mice with plasma phospholipid transfer protein overexpression. Arterioscler Thromb Vasc Biol 23:1601–1607PubMedCrossRef
13.
Zurück zum Zitat Schlitt A, Bickel C, Thumma P et al (2003) High plasma phospholipid transfer protein levels as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 23:1857–1862PubMedCrossRef Schlitt A, Bickel C, Thumma P et al (2003) High plasma phospholipid transfer protein levels as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 23:1857–1862PubMedCrossRef
14.
Zurück zum Zitat Dullaart RPF, Sluiter WJ, Dikkeschei LD, Hoogenberg K, Van Tol A (1994) Effect of adiposity on plasma lipid transfer protein activities: a possible link between insulin resistance and high density lipoprotein metabolism. Eur J Clin Invest 24:188–194PubMed Dullaart RPF, Sluiter WJ, Dikkeschei LD, Hoogenberg K, Van Tol A (1994) Effect of adiposity on plasma lipid transfer protein activities: a possible link between insulin resistance and high density lipoprotein metabolism. Eur J Clin Invest 24:188–194PubMed
15.
Zurück zum Zitat Riemens SC, Van Tol A, Sluiter WJ, Dullaart RPF (1998) Plasma phospholipid transfer protein activity is related to insulin resistance: impaired acute lowering by insulin in obese NIDDM patients. Diabetologia 41:929–934PubMedCrossRef Riemens SC, Van Tol A, Sluiter WJ, Dullaart RPF (1998) Plasma phospholipid transfer protein activity is related to insulin resistance: impaired acute lowering by insulin in obese NIDDM patients. Diabetologia 41:929–934PubMedCrossRef
16.
Zurück zum Zitat Kaser S, Sandhofer A, Föger B et al (2001) Influence of obesity and insulin sensitivity on phospholipid transfer protein activity. Diabetologia 44:1111–1117PubMedCrossRef Kaser S, Sandhofer A, Föger B et al (2001) Influence of obesity and insulin sensitivity on phospholipid transfer protein activity. Diabetologia 44:1111–1117PubMedCrossRef
17.
Zurück zum Zitat Riemens SC, Van Tol A, Sluiter WJ, Dullaart RPF (1998) Elevated plasma cholesteryl ester transfer in NIDDM: relationships with apolipoprotein B-containing lipoproteins and phospholipid transfer protein. Atherosclerosis 140:71–79PubMedCrossRef Riemens SC, Van Tol A, Sluiter WJ, Dullaart RPF (1998) Elevated plasma cholesteryl ester transfer in NIDDM: relationships with apolipoprotein B-containing lipoproteins and phospholipid transfer protein. Atherosclerosis 140:71–79PubMedCrossRef
18.
Zurück zum Zitat Desrumaux C, Athias A, Bessède G et al (1999) Mass concentration of plasma phospholipid transfer protein in normolipidemic, type IIa hyperlipidemic, type IIb hyperlipidemic, and non-insulin-dependent diabetic subjects as measured by a specific ELISA. Arterioscler Thromb Vasc Biol 19:266–275PubMed Desrumaux C, Athias A, Bessède G et al (1999) Mass concentration of plasma phospholipid transfer protein in normolipidemic, type IIa hyperlipidemic, type IIb hyperlipidemic, and non-insulin-dependent diabetic subjects as measured by a specific ELISA. Arterioscler Thromb Vasc Biol 19:266–275PubMed
19.
Zurück zum Zitat Tan KC, Shiu SW, Wong Y, Tam S (2005) Plasma phospholipid transfer protein activity and subclinical inflammation in type 2 diabetes mellitus. Atherosclerosis 178:365–370PubMedCrossRef Tan KC, Shiu SW, Wong Y, Tam S (2005) Plasma phospholipid transfer protein activity and subclinical inflammation in type 2 diabetes mellitus. Atherosclerosis 178:365–370PubMedCrossRef
20.
Zurück zum Zitat De Groot E, Hovingh GK, Wiegman A et al (2004) Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. Circulation 109 [23 Suppl 1]:III33–III38PubMed De Groot E, Hovingh GK, Wiegman A et al (2004) Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. Circulation 109 [23 Suppl 1]:III33–III38PubMed
21.
Zurück zum Zitat Selzer RH, Hodis HN, Kwong-Fu H et al (1994) Evaluation of computerized edge tracking for quantifying intima-media thickness of the common carotid artery from B-mode ultrasound images. Atherosclerosis 111:1–11PubMedCrossRef Selzer RH, Hodis HN, Kwong-Fu H et al (1994) Evaluation of computerized edge tracking for quantifying intima-media thickness of the common carotid artery from B-mode ultrasound images. Atherosclerosis 111:1–11PubMedCrossRef
22.
Zurück zum Zitat Speijer H, Groener JE, Van Ramshorst E, Van Tol A (1991) Different locations of cholesteryl ester transfer protein and phospholipid transfer protein activities in plasma. Atherosclerosis 90:159–168PubMedCrossRef Speijer H, Groener JE, Van Ramshorst E, Van Tol A (1991) Different locations of cholesteryl ester transfer protein and phospholipid transfer protein activities in plasma. Atherosclerosis 90:159–168PubMedCrossRef
23.
Zurück zum Zitat Howard G, Sharrett AR, Heiss G et al (1993) Carotid artery intimal-medial thickness distribution in general populations as evaluated by B-mode ultrasound. ARIC Investigators. Stroke 24:1297–1304PubMed Howard G, Sharrett AR, Heiss G et al (1993) Carotid artery intimal-medial thickness distribution in general populations as evaluated by B-mode ultrasound. ARIC Investigators. Stroke 24:1297–1304PubMed
24.
Zurück zum Zitat Psaty BM, Furberg CD, Kuller LH et al (1992) Isolated systolic hypertension and subclinical cardiovascular disease in the elderly. Initial findings from the Cardiovascular Health Study. JAMA 268:1287–1291PubMedCrossRef Psaty BM, Furberg CD, Kuller LH et al (1992) Isolated systolic hypertension and subclinical cardiovascular disease in the elderly. Initial findings from the Cardiovascular Health Study. JAMA 268:1287–1291PubMedCrossRef
25.
Zurück zum Zitat Bots ML, Hoes AW, Koudstaal PW, Hofman A, Grobbee DE (1997) Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997 96:1432–1437PubMed Bots ML, Hoes AW, Koudstaal PW, Hofman A, Grobbee DE (1997) Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997 96:1432–1437PubMed
26.
Zurück zum Zitat O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr (1999) Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 340:14–22PubMedCrossRef O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr (1999) Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 340:14–22PubMedCrossRef
27.
Zurück zum Zitat Matsumoto K, Sera Y, Nakamura H, Ueki Y, Myake S (2002) Correlation between common carotid arterial wall thickness and ischemic stroke in patients with type 2 diabetes mellitus. Metabolism 51:244–247PubMedCrossRef Matsumoto K, Sera Y, Nakamura H, Ueki Y, Myake S (2002) Correlation between common carotid arterial wall thickness and ischemic stroke in patients with type 2 diabetes mellitus. Metabolism 51:244–247PubMedCrossRef
28.
Zurück zum Zitat Melidonis A, Kyriazis IA, Georgopali A et al (2003) Prognostic value of the carotid artery intima-media thickness for the presence and severity of coronary artery disease in type 2 diabetic patients. Diab Care 26:3189–3190CrossRef Melidonis A, Kyriazis IA, Georgopali A et al (2003) Prognostic value of the carotid artery intima-media thickness for the presence and severity of coronary artery disease in type 2 diabetic patients. Diab Care 26:3189–3190CrossRef
29.
Zurück zum Zitat Pujia A, Gnasso A, Irace C, Colonna A, Mattioli PL (1994) Common carotid arterial wall thickness in NIDDM subjects. Diab Care 17:1330–1336CrossRef Pujia A, Gnasso A, Irace C, Colonna A, Mattioli PL (1994) Common carotid arterial wall thickness in NIDDM subjects. Diab Care 17:1330–1336CrossRef
30.
Zurück zum Zitat Niskanen L, Rauramaa R, Miettinen H, Haffner SM, Mercuri M, Uusitupa M (1996) Carotid artery intima-media thickness in elderly patients with NIDDM and in nondiabetic subjects. Stroke 27:1986–1992PubMed Niskanen L, Rauramaa R, Miettinen H, Haffner SM, Mercuri M, Uusitupa M (1996) Carotid artery intima-media thickness in elderly patients with NIDDM and in nondiabetic subjects. Stroke 27:1986–1992PubMed
31.
Zurück zum Zitat Metcalf PA, Folsom AR, Davis CE, Wu KK, Heiss G (2000) Haemostasis and carotid artery wall thickness in non-insulin dependent diabetes mellitus. Diabetes Res Clin Pract 47:25–35PubMedCrossRef Metcalf PA, Folsom AR, Davis CE, Wu KK, Heiss G (2000) Haemostasis and carotid artery wall thickness in non-insulin dependent diabetes mellitus. Diabetes Res Clin Pract 47:25–35PubMedCrossRef
32.
Zurück zum Zitat Henry RM, Kostense PJ, Spijkerman AM et al (2003) Arterial stiffness increases with deteriorating glucose tolerance status: the Hoorn Study. Circulation 107:2089–2095PubMedCrossRef Henry RM, Kostense PJ, Spijkerman AM et al (2003) Arterial stiffness increases with deteriorating glucose tolerance status: the Hoorn Study. Circulation 107:2089–2095PubMedCrossRef
33.
Zurück zum Zitat Zanchetti A, Crepaldi G, Bond MG et al (2001) Systolic and pulse blood pressures (but not diastolic blood pressure and serum cholesterol) are associated with alterations in carotid intima-media thickness in the moderately hypercholesterolaemic hypertensive patients of the Plaque Hypertension Lipid Lowering Italian Study. PHYLLIS study group. J Hypertens 19:79–88PubMedCrossRef Zanchetti A, Crepaldi G, Bond MG et al (2001) Systolic and pulse blood pressures (but not diastolic blood pressure and serum cholesterol) are associated with alterations in carotid intima-media thickness in the moderately hypercholesterolaemic hypertensive patients of the Plaque Hypertension Lipid Lowering Italian Study. PHYLLIS study group. J Hypertens 19:79–88PubMedCrossRef
34.
Zurück zum Zitat Heiss G, Sharrett R, Barnes R, Chambless LE, Szklo M, Alzola C (1991) Carotid atherosclerosis measured by B-mode ultrasound in populations: associations with cardiovascular risk factors in the ARIC study. Am J Epidemiol 134:250–256PubMed Heiss G, Sharrett R, Barnes R, Chambless LE, Szklo M, Alzola C (1991) Carotid atherosclerosis measured by B-mode ultrasound in populations: associations with cardiovascular risk factors in the ARIC study. Am J Epidemiol 134:250–256PubMed
35.
Zurück zum Zitat Safar ME, Levt BI, Struijker-Boudier H (2003) Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation 107:2864–2869PubMedCrossRef Safar ME, Levt BI, Struijker-Boudier H (2003) Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation 107:2864–2869PubMedCrossRef
36.
Zurück zum Zitat Benetos A, Waeber B, Izzo J et al (2002) Influence of age, risk factors, and cardiovascular and renal disease on arterial stiffness: clinical applications. Am J Hypertens 15:1101–1108PubMedCrossRef Benetos A, Waeber B, Izzo J et al (2002) Influence of age, risk factors, and cardiovascular and renal disease on arterial stiffness: clinical applications. Am J Hypertens 15:1101–1108PubMedCrossRef
37.
Zurück zum Zitat Hodis HN, Mack WJ (1998) Triglyceride-rich lipoproteins and progression of atherosclerosis. Eur Heart J 19 [Suppl A]:A40–A44PubMed Hodis HN, Mack WJ (1998) Triglyceride-rich lipoproteins and progression of atherosclerosis. Eur Heart J 19 [Suppl A]:A40–A44PubMed
38.
Zurück zum Zitat Temelkova-Kurktschiev T, Hanefeld M (2004) The lipid triad in type 2 diabetes—prevalence and relevance of hypertriglyceridaemia/low high-density lipoprotein syndrome in type 2 diabetes. Exp Clin Endocrinol Diabetes 112:75–79PubMedCrossRef Temelkova-Kurktschiev T, Hanefeld M (2004) The lipid triad in type 2 diabetes—prevalence and relevance of hypertriglyceridaemia/low high-density lipoprotein syndrome in type 2 diabetes. Exp Clin Endocrinol Diabetes 112:75–79PubMedCrossRef
39.
Zurück zum Zitat Vakkilainen J, Jauhiainen M, Ylitalo K et al (2002) LDL particle size in familial combined hyperlipidemia: effects of serum lipids, lipoprotein-modifying enzymes, and lipid transfer proteins. J Lipid Res 43:598–603PubMed Vakkilainen J, Jauhiainen M, Ylitalo K et al (2002) LDL particle size in familial combined hyperlipidemia: effects of serum lipids, lipoprotein-modifying enzymes, and lipid transfer proteins. J Lipid Res 43:598–603PubMed
40.
Zurück zum Zitat Tan KC, Shiu SW, Wong Y (2003) Plasma phospholipid transfer protein activity and small, dense LDL in type 2 diabetes mellitus. Eur J Clin Invest 33:301–306PubMedCrossRef Tan KC, Shiu SW, Wong Y (2003) Plasma phospholipid transfer protein activity and small, dense LDL in type 2 diabetes mellitus. Eur J Clin Invest 33:301–306PubMedCrossRef
41.
Zurück zum Zitat Schneider M, Verges B, Klein A et al (2004) Alterations in plasma vitamin E distribution in type 2 diabetic patients with elevated plasma phospholipid transfer protein activity. Diabetes 53:2633–2639PubMedCrossRef Schneider M, Verges B, Klein A et al (2004) Alterations in plasma vitamin E distribution in type 2 diabetic patients with elevated plasma phospholipid transfer protein activity. Diabetes 53:2633–2639PubMedCrossRef
42.
Zurück zum Zitat Tu AY, Albers JJ (2001) Glucose regulates the transcription of human genes relevant to HDL metabolism: responsive elements for peroxisome proliferator-activated receptor are involved in the regulation of phospholipid transfer protein. Diabetes 50:1851–1856PubMedCrossRef Tu AY, Albers JJ (2001) Glucose regulates the transcription of human genes relevant to HDL metabolism: responsive elements for peroxisome proliferator-activated receptor are involved in the regulation of phospholipid transfer protein. Diabetes 50:1851–1856PubMedCrossRef
43.
Zurück zum Zitat Oomen PHN, Van Tol A, Hattori H, Smit AJ, Scheek LM, Dullaart RPF (2005) Human plasma phospholipid transfer protein activity is decreased by acute hyperglycaemia: studies without and with hyperinsulinaemia in Type 1 diabetes mellitus. Diabet Med 22:768–774PubMedCrossRef Oomen PHN, Van Tol A, Hattori H, Smit AJ, Scheek LM, Dullaart RPF (2005) Human plasma phospholipid transfer protein activity is decreased by acute hyperglycaemia: studies without and with hyperinsulinaemia in Type 1 diabetes mellitus. Diabet Med 22:768–774PubMedCrossRef
Metadaten
Titel
Elevated plasma phospholipid transfer protein activity is a determinant of carotid intima-media thickness in type 2 diabetes mellitus
verfasst von
R. de Vries
G. M. Dallinga-Thie
A. J. Smit
B. H. R. Wolffenbuttel
A. van Tol
R. P. F. Dullaart
Publikationsdatum
01.02.2006
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 2/2006
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-005-0088-0

Weitere Artikel der Ausgabe 2/2006

Diabetologia 2/2006 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.